Rouzbeh Fateh, MD
Neurology · South San Francisco, CANPI 1215270533
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 92.2% of the total across 25 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 6 manufacturers reported payments, led by AbbVie at 33.6% of the total. Reporting peaked in 2019 at $909 and has fallen 81.3% since, to $170 in 2022. That places this record below the midpoint for neurology clinicians in CA, where the typical reported total is $885.
Across 25 payments — averaging $43.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$366
- Amgen$349
- Akcea Therapeutics, Inc.$283
- UCB, Inc.$44
- EMD Serono, Inc.$27
- Biohaven Pharmaceutical Holding Company Ltd.$21
What the payments were for
- Food & beverage$1,00592%
- Education$858%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 12 | $366 |
| Amgen | 6 | $349 |
| Akcea Therapeutics, Inc. | 4 | $283 |
| UCB, Inc. | 1 | $44 |
| EMD Serono, Inc. | 1 | $27 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,090 in reported general payments places this provider in the 50th percentile of 1,996 neurology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Memantine Hcl | 57 | $1,693 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 67 | $1,069 |
| Gabapentin | 65 | $1,033 |
| Propranolol Hcl ErPropranolol Hcl | 12 | $889 |
| Pregabalin | 19 | $675 |
| Duloxetine Hcl | 24 | $589 |
| Donepezil Hcl | 53 | $452 |
| Levetiracetam | 12 | $347 |
| Topiramate | 31 | $318 |
| Prednisone | 15 | $288 |
| Atorvastatin Calcium | 14 | $272 |
| Amitriptyline Hcl | 14 | $159 |
| Trazodone Hcl | 11 | $42 |
Paid to pharmacies, not to this prescriber.
Other neurology in South San Francisco
- Andrew BlumenfeldCarlsbad$4.9M
- Khashayar DashtipourLoma Linda$3.3M
- Regina BerkovichWest Hollywood$3M
- Daniel BandariNewport Beach$2.6M
- Perry ShiehLos Angeles$2.4M
- Sandeep ThakkarIrvine$2M
- David LiebeskindLos Angeles$1.9M
- Jack SchimCarlsbad$1.7M
- Parshaw DorrizMission Viejo$1.5M
- Benjamin FrishbergCarlsbad$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.